Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.
Anderson GR, Wardell SE, Cakir M, Crawford L, Leeds JC, Nussbaum DP, Shankar PS, Soderquist RS, Stein EM, Tingley JP, Winter PS, Zieser-Misenheimer EK, Alley HM, Yllanes A, Haney V, Blackwell KL, McCall SJ, McDonnell DP, Wood KC. Anderson GR, et al. Among authors: yllanes a. Sci Transl Med. 2016 Dec 14;8(369):369ra175. doi: 10.1126/scitranslmed.aae0348. Sci Transl Med. 2016. PMID: 27974663 Free PMC article.
CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC.
Stice JP, Wardell SE, Norris JD, Yllanes AP, Alley HM, Haney VO, White HS, Safi R, Winter PS, Cocce KJ, Kishton RJ, Lawrence SA, Strum JC, McDonnell DP. Stice JP, et al. Among authors: yllanes ap. Mol Cancer Res. 2017 Jun;15(6):660-669. doi: 10.1158/1541-7786.MCR-17-0028. Epub 2017 Feb 16. Mol Cancer Res. 2017. PMID: 28209757 Free PMC article.
Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.
Wardell SE, Yllanes AP, Chao CA, Bae Y, Andreano KJ, Desautels TK, Heetderks KA, Blitzer JT, Norris JD, McDonnell DP. Wardell SE, et al. Among authors: yllanes ap. Breast Cancer Res Treat. 2020 Jan;179(1):67-77. doi: 10.1007/s10549-019-05454-y. Epub 2019 Sep 27. Breast Cancer Res Treat. 2020. PMID: 31562570 Free PMC article.
Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer.
Norris JD, Ellison SJ, Baker JG, Stagg DB, Wardell SE, Park S, Alley HM, Baldi RM, Yllanes A, Andreano KJ, Stice JP, Lawrence SA, Eisner JR, Price DK, Moore WR, Figg WD, McDonnell DP. Norris JD, et al. Among authors: yllanes a. J Clin Invest. 2017 Jun 1;127(6):2326-2338. doi: 10.1172/JCI87328. Epub 2017 May 2. J Clin Invest. 2017. PMID: 28463227 Free PMC article.
Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy.
Wardell SE, Yllanes AP, Chao CA, Bae Y, Andreano KJ, Desautels TK, Heetderks KA, Blitzer JT, Norris JD, McDonnell DP. Wardell SE, et al. Among authors: yllanes ap. Breast Cancer Res Treat. 2020 Feb;179(3):769. doi: 10.1007/s10549-019-05498-0. Breast Cancer Res Treat. 2020. PMID: 31734822 Free PMC article.
The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer.
Cocce KJ, Jasper JS, Desautels TK, Everett L, Wardell S, Westerling T, Baldi R, Wright TM, Tavares K, Yllanes A, Bae Y, Blitzer JT, Logsdon C, Rakiec DP, Ruddy DA, Jiang T, Broadwater G, Hyslop T, Hall A, Laine M, Phung L, Greene GL, Martin LA, Pancholi S, Dowsett M, Detre S, Marks JR, Crawford GE, Brown M, Norris JD, Chang CY, McDonnell DP. Cocce KJ, et al. Among authors: yllanes a. Cell Rep. 2019 Oct 22;29(4):889-903.e10. doi: 10.1016/j.celrep.2019.09.032. Cell Rep. 2019. PMID: 31644911 Free PMC article.